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Summary
Background The appropriate age range for breast cancer screening remains a matter of debate. We aimed to estimate 
the effect of mammographic screening at ages 40–48 years on breast cancer mortality.
Methods We did a randomised, controlled trial involving 23 breast screening units across Great Britain. We randomly 
assigned women aged 39–41 years, using individual randomisation, stratified by general practice, in a 1:2 ratio, to 
yearly mammographic screening from the year of inclusion in the trial up to and including the calendar year that they 
reached age 48 years (intervention group), or to standard care of no screening until the invitation to their first National 
Health Service Breast Screening Programme (NHSBSP) screen at approximately age 50 years (control group). Women 
in the intervention group were recruited by postal invitation. Women in the control group were unaware of the study. 
The primary endpoint was mortality from breast cancers (with breast cancer coded as the underlying cause of death) 
diagnosed during the intervention period, before the participant’s first NHSBSP screen. To study the timing of the 
mortality effect, we analysed the results in different follow-up periods. Women were included in the primary 
comparison regardless of compliance with randomisation status (intention-to-treat analysis). This Article reports on 
long-term follow-up analysis. The trial is registered with the ISRCTN registry, ISRCTN24647151.
Findings 160 921 women were recruited between Oct 14, 1990, and Sept 24, 1997. 53 883 women (33·5%) were 
randomly assigned to the intervention group and 106 953 (66·5%) to the control group. Between randomisation and 
Feb 28, 2017, women were followed up for a median of 22·8 years (IQR 21·8–24·0). We observed a significant 
reduction in breast cancer mortality at 10 years of follow-up, with 83 breast cancer deaths in the intervention group 
versus 219 in the control group (relative rate [RR] 0·75 [95% CI 0·58–0·97]; p=0·029). No significant reduction was 
observed thereafter, with 126 deaths versus 255 deaths occurring after more than 10 years of follow-up (RR 0·98 
[0·79–1·22]; p=0·86).
Interpretation Yearly mammography before age 50 years, commencing at age 40 or 41 years, was associated with a 
relative reduction in breast cancer mortality, which was attenuated after 10 years, although the absolute reduction 
remained constant. Reducing the lower age limit for screening from 50 to 40 years could potentially reduce breast 
cancer mortality.
Funding National Institute for Health Research Health Technology Assessment programme.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
The UK, along with many other countries, has a breast 
cancer screening programme offering mammography to 
women aged 50–70 years every 3 years.1 There remains 
uncertainty as to the appropriate age at which to start 
screening, specifically about whether to screen women 
younger than 50 years.2 Recommendations from official 
and charitable bodies vary.3–5 Mammographic screening in 
this age group presents a greater challenge than at older 
ages in both radiological and public health terms. First, 
the typical composition of the breast is more radiologically 
dense in younger women, reducing the sensitivity of 
mammo graphy.6 Second, breast cancer incidence and 
mortality are lower in women younger than 50 years than 
in women aged 50 years and older, so the potential 
absolute gain from screening is lower.2 Third, there is 
evidence that tumours in younger women progress more 
rapidly, are more likely to be oestrogen receptor negative, 
and have unfavourable histological grade.5,7 Thus, there 
remains interest in the effects, both favourable and 
unfavourable, of mammography screening in women 
aged 40–49 years.
Two major UK studies of mammographic screening 
before 50 years of age are the AgeX trial8 of extending the 
screening age range to 47–73 years, and the UK Age trial9 
of yearly screening from the age of 40 years. The AgeX 
trial is not expected to report results until 2026. The UK 
Age trial reported 17-year follow-up results in 2015, 
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showing a reduction in breast cancer mortality with 
yearly screening from the age of 40 years, which was 
significant in the first 10 years after randomisation, and 
was attenuated thereafter.9 In this paper, we report on 
breast cancer incidence and mortality results in the UK 
Age trial after 23 years of follow-up.
Methods
Study design and participants
The design of the UK Age trial has been described 
elsewhere.10 In brief, women aged 39–41 years were 
randomly assigned to yearly screening up to and 
including the calendar year that they reached age 48 years 
(intervention group), or to usual care, which was no 
screening until the first National Health Service Breast 
Screening Programme (NHSBSP) screen at approxi-
mately 50 years of age (control group). The trial was 
conducted in 23 breast screening units in England, 
Wales, and Scotland. Women were identified from 
general practitioner (GP) lists, which were then held by 
Family Health Services Authorities. There were no 
formal exclusions on the grounds of comorbidities. 
However, GPs were informed of which of their patients 
were on the randomisation lists and could remove 
women whom they considered unsuitable for invitation. 
Recruitment by centre is shown in the appendix (p 1).
Women in the intervention group were invited to 
participate by post. They received a trial information 
leaflet with their letter of invitation. Acceptance of the 
invitation to attend screening was taken to be informed 
consent to participate in the trial. The women in the 
uninvited control group were unaware of their inclusion 
in the trial, which was deemed acceptable because it was 
analogous to a geographically distinct population that are 
followed up to monitor cancer and mortality and receive 
no deviation from the usual care.9 Ethics approval was 
obtained from the London Central Research Ethics 
Committee.
Randomisation and masking
Women were randomly assigned (1:2) to the intervention 
group or control group. From April 1, 1992, onwards, ran-
domisation and allocation to trial group were carried out 
on the Health Authorities computer system using ad hoc 
software. Randomisation used computerised random 
number generation and was done by Health Authority 
personnel independently of the screening centres and 
without the screening services having previous sight of 
the randomisation status. Before this, in three centres 
that started the trial early, when randomisation on the 
system was not yet available to the trial, random number 
lists were generated, also from a computerised random 
number generator, by the trial coordinators and applied 
to GP practice lists. This randomisation was also done 
independently of screening services, without their 
knowledge of randomisation status. It was not feasible to 
blind the screening services thereafter, because they had 
to deliver the screening to the intervention group. 
Individual randomisation was done, stratified by GP 
practice, so that a third of the women in any practice 
were allocated to the intervention group, but other-
wise randomisation was unrestricted and unblocked. For 
each general practice, the entire random isation allocation 
was performed in a single run.
Procedures
Screening in the trial was by two-view film (analogue) 
mammography at the first screen, with single view 
Research in context
Evidence before this study
We searched PubMed with no date or language restrictions with 
the search terms “breast” AND “screening” AND 
“mammography” AND “age” AND “trial”. This search yielded 
eight trials. Results from all the trials (except the UK Age trial) 
included the effect of screening after participants younger than 
50 years at randomisation reached age 50 years. In meta-
analyses of these trials, Cochrane and US Preventive Services 
Task Force reviews found 13–16% reductions in breast cancer 
mortality with invitation to screening before age 50 years. 
There is considerable uncertainty about overdiagnosis of breast 
cancer in this age group, as previous estimates vary widely.
Previous publications from the UK Age trial indicated an early 
relative reduction in breast cancer mortality with the 
intervention of screening beginning at age 40 or 41 years, and 
this reduction was attenuated after 10 years. Results on breast 
cancer incidence indicated little or no overdiagnosis in addition 
to that which would occur from screening those aged 50 years 
and older.
Added value of this study
The results here, with 6 additional years of follow-up since the 
last publication, confirm the early reduction in breast cancer 
mortality associated with annual mammographic screening 
commencing at age 40 or 41 years. The relative rate of breast 
cancer mortality was not significantly different after 10 years, 
but the absolute reduction remains roughly constant. Our 
results confirm the finding of minimal overdiagnosis beyond 
that which would occur when screening those aged 50 years 
and older.
Implications of all the available evidence
Mammographic screening between the ages of 40 and 49 years 
reduces breast cancer mortality and adds little to the burden of 
overdiagnosis. There is a need for research to clarify whether 
substantial progress in both early-detection technology and 
treatment of breast cancer might modify the reduction in 
breast cancer mortality observed in randomised controlled trials 
of screening in the age group of 40–49 years.
See Online for appendix
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thereafter, unless otherwise indicated. Mammograms 
were double read (both reads done locally). All women in 
the intervention group were re-invited for screening 
yearly unless they requested otherwise. Women who 
moved to areas not covered by the trial were not re-invited 
for screening as part of the trial, but were able to self-
refer to either their previous or their nearest participating 
screening centre. Screening in three centres ceased 
prematurely (after four, five, and six rounds of screening) 
due to the inability of the centres to manage the additional 
workload.
Women were flagged with the National Health Service 
(NHS) Central Register, and the trialists have been 
notified of all breast cancers, breast cancer deaths, and 
deaths from all other causes, up to Feb 28, 2017. Since 
2015, notifications were supplied by NHS Digital. At the 
age of 50 years, both groups became eligible for invitation 
to screening every 3 years as part of the NHSBSP, and 
received their first invitation between age 50 and 52 years. 
The intervention phase of the trial ceased for each 
participant when they were invited to their first NHSBSP 
screen. Cessation in all centres followed this protocol, 
except for three centres that had to stop screening early 
because of logistic and capacity issues.
Outcomes
The primary endpoint was mortality from breast cancers 
diagnosed in the intervention period of the trial. This was 
defined as deaths from all breast cancers diagnosed after 
randomisation, but before first NHSBSP invitation, in 
both groups. A death was considered to be from breast 
cancer if it was given as the underlying cause of death on 
the death certificate. Secondary endpoints were mortality 
from all breast cancers diagnosed after randomisation 
until the data cutoff date, all-cause mortality (in the entire 
trial population and in the subgroup of women with breast 
cancer), mortality from causes other than breast cancer (in 
the entire trial population and in the subgroup of women 
with breast cancer), and incidence of breast cancer.
Statistical analysis
Originally, the trial had been planned to include 
195 000 partici pants, planning an analysis at 10 years; 
however, this number was revised in view of slower 
recruitment and an amended estimate of the likely 
control group breast cancer mortality rate. Consequently, 
the trial was designed to have 90% power to detect a 
20% reduction in breast cancer mortality in the inter-
vention group at 14 years of follow-up, assuming 30% 
non-compliance, a control group mortality rate of 0·317 
per 1000 person-years of follow-up, and one-sided testing. 
This trial design would have required 65 000 women in 
the intervention group and 130 000 in the control group. 
Because of the capacity issues in the screening units, the 
Trial Steering and Data Monitoring Committees decided 
that recruitment should cease at 160 000 participants, 
which would give 80% power to detect a reduction of 
24% in breast cancer mortality in the intervention group 
at 10 years of follow-up. The Trial Management Group 
decided that two-sided testing should be used, to reduce 
the risk of a false-positive trial result. With 160 000 partici-
pants (53 000 in the intervention group and 107 000 in 
the control group) and two-sided testing, there was 
88% power to detect a reduction of 26% at 14 years of 
follow-up with two-sided testing. A p value of less than 
0·05 was considered significant.
Mortality data, from breast cancer, other causes, and all 
causes, were analysed by Poisson regression, for purposes 
of significance testing between the intervention group 
and control group, and estimation of relative rates (RR) 
for the intervention group compared to the control group, 
and 95% CIs for these rates.11 Nelson-Aalen estimates of 
cumulative hazard were also calculated.12 Incidence data 
were analysed with the same methods as for mortality 
data. The primary analysis compared the mortality 
outcome between the entire intervention group and 
control group on the principle of intention to treat. We 
also estimated the per-protocol effect of being screened, 
adjusted for self-selection bias by the method of Cuzick 
and colleagues.13
In estimating the effect on mortality from cancers 
diagnosed in the intervention period of the trial, there is 
a potential bias against the intervention. This bias arises 
because the intervention group will include mortality 
from cancers diagnosed at screening that otherwise 
would have been diagnosed at or after the first NHSBSP 
screen, and for which the equivalent deaths would 
therefore not be included in the control group. This bias 
can be minimised by including cancers diagnosed at a 
contemporaneous screen at the end of the intervention 
period in both groups.14 We therefore did a secondary 
post-hoc analysis redefining the intervention period 
cancers as those diagnosed up to and including the first 
NHSBSP screen in both groups. Thus, this endpoint 
was mortality from all breast cancers diagnosed after 
randomisation and either before or at the first NHSBSP 
screen in both groups. We also analysed mortality from 
all causes, from causes other than breast cancer, from all 
cancers (including breast cancer), and from ischaemic 
heart disease. This included analyses of deaths from all 
causes, and from all causes except breast cancer, within 
the women with breast cancer, to determine whether 
there was bias in cause-of-death ascertainment.
We undertook one further post-hoc analysis, estimating 
years of life saved from breast cancer in the intervention 
group, by calculating the years lost to breast cancer up to 
the final follow-up date of Feb 28, 2017. We then 
subtracted the average life-years lost in the intervention 
group from the average life-years lost in the control 
group. Significance of the difference between groups was 
calculated by bootstrap methods.15 We then calculated a 
test-based 95% CI on the total years of life saved from 
breast cancer in the intervention group, on the basis of 
the bootstrap significance test.
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All statistical analyses were done with Stata 
(version 15.1). The trial protocol is given in the appendix 
(pp 2–6). This trial is registered with the ISRCTN registry, 
ISRCTN24647151.
Role of the funding source
The funders of the trial had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. SMM, DV, DP, and SWD had access to raw 
data. The corresponding author had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Recruitment took place between Oct 14, 1990, and 
Sept 24, 1997. 160 921 women were randomly assigned to 
either the intervention group (n=53 914) or control group 
(n=107 007; figure 1). After exclusions and losses to 
tracing, there were 53 883 women (99·9% of those 
randomly assigned) in the intervention group and 
106 953 (99·9%) in the control group included in the 
analysis. As reported by Johns and colleagues,16 at first 
invitation, participation in screening was 36 622 screens 
(68·1%) following 53 801 invitations in the intervention 
group and subsequently was 176 746 (69·1%) following 
255 618 invi tations. There were 2134 (4·9%) false 
positives of 43 709 results at first intervention screen (not 
neces sarily first invitation) and 7041 (3·2%) of 216 930 at 
subsequent intervention screens. Of those attending 
screening during the intervention period, 7893 (18·1%) 
of 43 709 women had at least one false-positive result.17 
In terms of attrition due to all-cause mortality, emigra-
tion, or other loss to follow-up, 150 909 (93·8%) of 
160 836 women completed 20-year follow-up, 38 988 
(24·2%) completed 24-year follow-up, and 9605 (5·9%) 
completed 25-year follow-up (with equal relative pro-
portions in the intervention group and control group; 
data not shown). Participants were followed up for a 
median of 22·8 years (IQR 21·8–24·0) until the final data 
cutoff date of Feb 28, 2017.
In the total follow-up period, there were 10 439 deaths, 
683 (7%) of which were breast cancer deaths from breast 
cancers diagnosed during the intervention period. Breast 
cancer mortality, as of Feb 28, 2017, from breast cancers 
diagnosed during the intervention period is shown in 
table 1. The cumulative mortality graphs are given in 
figure 2A. Mortality by cancer grade is shown in the 
appendix (p 7). At 10 years of follow-up, breast cancer 
mortality was significantly lower in the intervention 
group than in the control group, with 83 deaths in the 
intervention group versus 219 deaths in the control 
group (RR 0·75 [95% CI 0·58–0·97]; p=0·029). After 
more than 10 years of follow-up, no significant difference 
in breast cancer mortality was observed in the 
intervention group compared with the control group, 
with 126 deaths versus 255 deaths occurring in this 
period (0·98 [0·79–1·22]; p=0·86). Overall, there was no 
significant reduction in breast cancer mortality in the 
intervention group compared with the control group, 
with 209 deaths in the intervention group versus 
474 deaths in the control group by the end of follow-up 
(0·88 [0·74–1·03]; p=0·13).
The per-protocol effect of being screened in the 
intervention period, adjusted for selection bias, was a 
significant reduction in breast cancer mortality in the 
intervention group compared with the control group at 
10 years after randomisation (RR 0·66 [95% CI 0·46–0·95]; 
p=0·025), no significant reduction after more than 
10 years of follow-up (0·98 [0·75–1·27]; p=0·89), and no 
significant reduction overall (0·84 [0·68–1·04]; p=0·11).
Table 1 also shows breast cancer mortality for the 
secondary post-hoc analysis of cancers diagnosed up to 
and including the first NHSBSP screen in both groups. 
At 10 years after randomisation, results were similar to 
160 921 women enrolled
53 914 assigned to intervention group (yearly 
 screening up to age 48 years)
51 882 invited for NHSBSP screening from age 
 50–52 years
53 883 analysed
31 excluded
 8 not traced
 10 deceased before entry   
 7 emigrated before entry 
 6 found to be men
107 007 assigned to control group (usual care:
 no screening until NHSBSP invitation)
103 128 invited for NHSBSP screening from age 
 50–52 years
106 953 analysed
54 excluded
 8 not traced
 19 deceased before entry   
 15 emigrated before entry 
 12 found to be men
Figure 1: Trial profile
NHSBSP=National Health Service Breast Screening Programme. It could not be guaranteed that some of the 
women diagnosed with breast cancer before age 50 years did not receive an invitation to NHSBSP screening.
Intervention group Control group RR (95% CI)
Deaths, n Follow-up, 
person-years
Deaths, n Follow-up, 
person-years
Cancers diagnosed in the intervention period, up to immediately before first NHSBSP screen (primary 
analysis)
Total 209 1 201 010 474 2 385 006 0·88 (0·74–1·03)
Observation period
<10 years 83 532 729 219 1 058 236 0·75 (0·58–0·97)
≥10 years 126 668 281 255 1 326 770 0·98 (0·79–1·22)
Cancers diagnosed in the period up to and including the first NHSBSP screen (post-hoc analysis)
Total 216 1 201 010 498 2 385 006 0·86 (0·73–1·01)
Observation period
<10 years 83 532 729 219 1 058 236 0·75 (0·58–0·97)
≥10 years 133 668 281 279 1 326 770 0·95 (0·77–1·17)
RR=relative rate. NHSBSP=National Health Service Breast Screening Programme.
Table 1: Mortality from breast cancers by period of cancer diagnosis and follow-up period
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the primary analysis; there was a significant reduction in 
mortality in the intervention group, with 83 deaths in the 
intervention group versus 219 deaths in the control group 
(RR 0·75 [95% CI 0·58–0·97]; p=0·029). After more than 
10 years of follow-up, no significant reduction was 
observed, with 133 deaths versus 279 deaths (0·95 
[0·77–1·17]; p=0·63). Overall, there was no significant 
difference, with 216 deaths versus 498 deaths (0·86 
[0·73–1·01]; p=0·068).
The absolute difference in breast cancer mortality was 
–0·6 deaths per 1000 women invited for screening 
(95% CI –1·3 to 0·1). This corresponds to 1667 women 
needing to be invited and, given the 69% average 
participation rate, 1150 needing to screen in the age 
group of 40–49 years to prevent one breast cancer death, 
or slightly less than one breast cancer death prevented 
per 1000 screened. This finding was relatively stable over 
time, as can be seen by the roughly constant distance 
between the two mortality curves in figure 2A. In a post-
hoc analysis, there were 8442·5 (95% CI 7766·2–9118·7) 
years of life lost to breast cancer in the control group, 
78·9 years per thousand women, and 3632·4 (95% CI 
3201·1–4063·6) years of life lost to breast cancer in the 
intervention group, 67·4 years per thousand women. 
Thus, there were 11·5 (95% CI 1·0–22·0) years saved per 
thousand women invited (p=0·031), or 620 years of life 
saved in total.
No significant difference in all-cause mortality was 
found between the two groups by the end of follow-up, 
with 3507 deaths in the intervention group versus 
6932 deaths in the control group (RR 1·01 [95% CI 
0·96–1·05]; p=0·66). Mortality from causes other than 
breast cancer was also not different between the 
two groups, with 3169 deaths versus 6189 deaths (1·02 
[0·97–1·07]; p=0·43). We also analysed deaths from all 
cancers (including breast cancer) and from ischaemic 
heart disease. There was no significant difference between 
groups in deaths from all cancers, with 1770 deaths versus 
3564 deaths (0·99 [0·93–1·05]; p=0·74), or in deaths from 
ischaemic heart disease, with 230 deaths versus 444 deaths 
(1·03 [0·87–1·20]; p=0·72).
We also investigated deaths from all causes, and from 
all causes except breast cancer, within the women with 
breast cancer, to determine whether treatment of cancers 
had a differential effect on mortality between the inter-
vention group and control group. There was a significant 
reduction in death from any cause in women with breast 
cancer in the intervention group, with 418 deaths in the 
intervention group versus 928 deaths in the control 
group (RR 0·87 [95% CI 0·77–0·98]; p=0·024), and no 
significant reduction in deaths from all causes except 
breast cancer in the intervention group, with 93 deaths 
versus 208 deaths (0·86 [95% CI 0·67–1·11]; p=0·24).
The cumulative incidence of breast cancer by trial 
group is shown in figure 2B, and breast cancer 
incidence by trial group and by period of follow-up 
is shown in table 2. For total cancers, up to just before 
the first NHSBSP screen, there were 953 breast cancers 
in the intervention group versus 1731 breast cancers in 
the control group (RR 1·09 [95% CI 1·00–1·19]; 
p=0·047). Up to and including the first NHSBSP 
screen, there were 1125 cancers versus 2247 cancers 
(0·99 [0·93–1·07]; p=0·79). At the end of follow-up, 
there were 2617 cancers versus 5260 cancers (0·99 
[0·94–1·04]; p=0·70). Thus, there was no difference in 
total breast cancer incidence between the intervention 
group and the control group, including after NHSBSP 
screening had commenced. The results show no 
significant differences between groups with respect to 
incidence of invasive cancers. More in-situ cancers 
were reported in the intervention group during the 
intervention period than in the control group, which 
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Figure 2: Breast cancer mortality and incidence
(A) Cumulative breast cancer mortality from randomisation to end of follow-up, from cancers diagnosed during 
the intervention period of the trial. (B) Cumulative incidence of breast cancer of any type, from randomisation to 
end of follow-up. Initial numbers are smaller than the totals analysed for mortality because women with breast 
cancer before randomisation have been excluded from the analysis of breast cancer incidence.
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was attenuated with no significant difference by the 
end of follow-up (table 2).
Discussion
The results of the UK Age trial at 23 years of follow-up 
mostly confirm those reported after 17 years of follow-up.9 
There was a substantial and significant reduction in 
breast cancer mortality, of the order of 25%, associated 
with the invitation to yearly mammography between age 
40 and 49 years in the first 10 years. This effect was 
attenuated thereafter, with little or no effect of the 
intervention on breast cancer deaths occurring 10 years 
or more after randomisation. However, the absolute 
benefit remained roughly constant up to the end of 
follow-up, with approximately one death prevented per 
1000 women screened.
With the 17-year results, we speculated that the absence 
of an effect after 10 years was due to a lesser effect of the 
intervention on mortality from grade 3 tumours, whereby 
some breast cancer deaths were postponed rather than 
prevented. The updated results here do not confirm this 
postponement theory, given that the absolute reduction 
in breast cancer mortality remained approximately 
constant in the long term. However, the updated data are 
consistent with the intervention having a lesser effect on 
mortality from grade 3 cancers. There was a substantial 
reduction in mortality in the intervention group from 
grade 1 and 2 breast cancers, but no difference in mortality 
from grade 3 breast cancers. Similarly, survival with 
grade 1 and 2 breast cancers in the intervention group 
was higher than that of the corresponding cancers in the 
control group, whereas survival from grade 3 breast 
cancers was the same in both groups.18 It should be noted 
that in the Swedish Two-County trial,19 in women aged 
40–74 years (73% of whom were aged 50 years or older), 
most of the breast cancer mortality reduction was in 
grade 3 cancers. However, they also found a reduced 
effect on grade 3 cancers in the age group of 40–49 years.7
The significant early effect on breast cancer mortality, 
which loses significance with long-term follow-up, 
reflects the fact that the deaths prevented by the 
intervention were in the first 10 years after randomisation. 
However, there were no compensatory additional breast 
cancer deaths after 10 years of follow-up, and so the 
absolute benefit from the intervention remains the same 
in the long term. This finding is not unprecedented in 
cancer screening. The National Lung Screening trial20 in 
the USA found that the absolute number of lung cancer 
deaths prevented by low-dose CT screening remained 
roughly constant from 6 years to 13 years of follow-up, 
whereas the relative reduction in lung cancer mortality 
was attenuated from 20% at 6 years to 14% at 13 years.
Overall, our results are consistent with a meta-analysis 
of the randomised trials of mammography.21 However, 
our trial specifically recruited women at ages 39–41 years, 
so that all of the trial screening would take place before 
the age of 50 years. The other trials did not have this 
design feature.
There was no indication of an effect of the intervention 
on deaths from causes other than breast cancer, and no 
effect on all-cause mortality. The latter is to be expected, 
since the effect on all-cause mortality is overwhelmingly 
driven by causes of death on which the intervention has 
no effect.22 In this trial, breast cancer deaths from cancers 
diagnosed in the intervention phase comprised only 
683 (7%) of all 10 439 deaths. It is also of interest that there 
was no evidence of an increase in deaths from causes 
other than breast cancer in women diagnosed with breast 
cancer in the inter vention group. It has been suggested 
that the observed reduction in breast cancer mortality in 
Intervention group Control group Intervention group vs 
control group, 
RR (95% CI)
Breast cancers, n Follow-up, 
person-years
Breast cancers, n Follow-up, 
person-years
Invasive cancers only
Intervention period 835 569 632 1628 1 129 985 1·02 (0·94–1·11)
Up to and including first NHSBSP screen 970 569 632 2021 1 129 985 0·95 (0·88–1·04)
By the end of follow-up 2288 1 177 990 4640 2 339 852 0·98 (0·93–1·03)
In-situ cancers only
Intervention period 118 573 221 103 1 137 432 2·27 (1·75–2·95)
Up to and including first NHSBSP screen 155 573 221 226 1 137 432 1·36 (1·11–1·67)
By the end of follow-up 329 1 195 224 620 2 375 349 1·05 (0·92–1·20)
All cancers
Intervention period 953 569 016 1731 1 129 491 1·09 (1·00–1·19)
Up to and including first NHSBSP screen 1125 569 016 2247 1 129 491 0·99 (0·93–1·07)
By the end of follow-up 2617 1 174 649 5260 2 334 516 0·99 (0·94–1·04)
Intervention period was defined as the period from randomisation up to immediately before first NHSBSP screen. RRs and 95% CIs are for incidence of breast cancer in 
intervention group compared with control group. RR=relative rate. NHSBSP=National Health Service Breast Screening Programme.
Table 2: Cumulative incidence of breast cancer by trial group, cancer type, and follow-up period
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this trial and other screening trials could be because of 
misclassification of cause of death or failure to count 
deaths from other causes in women with breast cancer as 
an indirect effect of the screening (such as heart disease 
deaths as a result of increased use of radiotherapy).23 The 
absence of an increase in risk of death from other causes 
in women with breast cancer in the intervention group in 
this study suggests that this concern is unwarranted.
Results with respect to breast cancer incidence suggest 
at worst modest overdiagnosis in this age group, and that 
any overdiagnosed cancers would otherwise be diagnosed 
at NHSBSP screening from age 50 years onwards. 
Therefore, screening in the age group of 40–49 years does 
not appear to add to overdiagnosed cases from screening 
at age 50 years and older. There might have been some 
overdiagnosis in the intervention group and during the 
intervention period, which was balanced when the control 
group received screening in the NHSBSP. However, we 
cannot directly observe or estimate overdiagnosis in a trial 
in which the control group also receives screening, albeit 
later than the intervention group.
There are several limitations to this study, some 
relating to the period of the intervention. The screening 
in the intervention period took place throughout the 
1990s and early 2000s, during which considerable 
changes in diagnosis, screening, and therapy took place. 
The screening method was film screening and was 
mainly single-view mammography. The average non-
participation rate was 31%, and three centres had to cease 
screening early because of capacity problems.9,16 These 
factors suggest that the mortality benefit observed in the 
trial is conservative. On the one hand, since therapies 
have changed substantially in recent decades, there 
might be less scope for screening to reduce mortality in 
our current era. On the other hand, recent results suggest 
that even with effective adjuvant systemic therapies, 
there is still a substantial survival advantage from 
diagnosis and treatment at an early stage.24,25
Our results suggest a reduction in breast cancer mortality 
with annual mammography in women aged 40–49 years 
within the first 10 years of follow-up, and no overdiagnosis 
in addition to that which arises from screening at age 
50 years and older. Further evaluation of screening in 
women younger than 50 years, with modern screening 
and treatment protocols, is warranted.
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